{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:09:30Z","timestamp":1789556970130,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejca.2017.12.011","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T11:26:02Z","timestamp":1517484362000},"page":"92-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring"],"prefix":"10.1016","volume":"91","author":[{"given":"Mart","family":"Schiefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-8067","authenticated-orcid":false,"given":"Trang","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5155-0163","authenticated-orcid":false,"given":"Ulrich","family":"Lalji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10048","key":"10.1016\/j.ejca.2017.12.011_bib1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer","volume":"388","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejca.2017.12.011_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.12.011_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.12.011_bib4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.12.011_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2017.12.011_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2017.12.011_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1753465816670498","article-title":"Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience","volume":"10","author":"Sullivan","year":"2016","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"10.1016\/j.ejca.2017.12.011_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/annonc\/mds503","article-title":"A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and\/or metastatic squamous-cell carcinoma of the head and neck","volume":"24","author":"Abdul Razak","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.12.011_bib9","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian","year":"2014","journal-title":"Oncologist"},{"issue":"Spec Feature","key":"10.1016\/j.ejca.2017.12.011_bib10","first-page":"163","article-title":"Zykadia (ceritinib) approved for patients with crizotinib-resistant ALK-positive non-small-cell lung cancer","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.ejca.2017.12.011_bib11","unstructured":"EMA. Summary of the risk management plan (RMP) for Tagrisso (osimertinib). 03-Oct-2017; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004124\/WC500202022.pdf."},{"issue":"19","key":"10.1016\/j.ejca.2017.12.011_bib12","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2017.12.011_bib13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.CIR.99.4.518","article-title":"Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II","volume":"99","author":"Priori","year":"1999","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ejca.2017.12.011_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"issue":"131","key":"10.1016\/j.ejca.2017.12.011_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003623","article-title":"Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome","volume":"4","author":"Lu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2017.12.011_bib16","unstructured":"EMA. EPAR crizotinib. 10-Oct-2017; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002489\/WC500134759.pdf."},{"key":"10.1016\/j.ejca.2017.12.011_bib17","unstructured":"EMA. Summary of the risk management plan (RMP) for Zykadia (ceritinib). 06-Oct-2017; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Risk-management-plan_summary\/human\/003819\/WC500183128.pdf."},{"issue":"19","key":"10.1016\/j.ejca.2017.12.011_bib18","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1001\/archinternmed.2011.433","article-title":"QT-interval duration and mortality rate: results from the third National Health and Nutrition Examination Survey","volume":"171","author":"Zhang","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejca.2017.12.011_bib19","unstructured":"Skinner, J.et\u00a0al. Guidelines for the diagnosis and management of Familial Long QT Syndrome. 2011 01-nov-2017; Available from: http:\/\/www.csanz.edu.au\/documents\/guidelines\/clinical_practice\/Familial_Long_QT_Syndrome.pdf."},{"key":"10.1016\/j.ejca.2017.12.011_bib20","unstructured":"EMA. EPAR gefitinib. access date 01-nov-2017; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001016\/WC500036358.pdf."},{"key":"10.1016\/j.ejca.2017.12.011_bib21","unstructured":"EMA. EPAR erlotinib. access date 01-nov-2017; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000618\/WC500033994.pdf."},{"key":"10.1016\/j.ejca.2017.12.011_bib22","unstructured":"EMA. EPAR afatinib. access date 01-nov-2017; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002280\/WC500152392.pdf."},{"issue":"11","key":"10.1016\/j.ejca.2017.12.011_bib23","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.12.011_bib24","unstructured":"EMA. EPAR alectinib. 01-nov-2017; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004164\/WC500225707.pdf."},{"key":"10.1016\/j.ejca.2017.12.011_bib25","unstructured":"FDA. FDA prescribing information brigatinib. 01-nov-2017; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208772lbl.pdf."},{"key":"10.1016\/j.ejca.2017.12.011_bib26","series-title":"PF-06463922 named-patient early access reference guide for physicians, Version 2.0, 05 August 2016","author":"Pfizer","year":"2016"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917314909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T09:58:19Z","timestamp":1535104699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917314909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":26,"alternative-id":["S0959804917314909"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.12.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}